Serum s100B in Generalized Vitiligo and Its Relation to Oral Baricitinib, Narrow Band Ultraviolet (B) Therapy
Status: Recruiting
Location: See location...
Intervention Type: Drug, Radiation
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 75
Healthy Volunteers: t
View:
• active generalized vitiligo patients with body surface area involved \>5% excluding hands and feet
• no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.
Locations
Other Locations
Egypt
Qena university hospital, Qena faculty of medicine
RECRUITING
Qina
Contact Information
Primary
Eman A Osman, bachelor
em.ea01127@gmail.com
+20 1127052748
Backup
Hassan mo farid, bachelor
dr.hassanfarid96@gmail.com
+201040435051
Time Frame
Start Date: 2024-10-02
Estimated Completion Date: 2025-10
Participants
Target number of participants: 50
Treatments
Active_comparator: baricitinib
group A, vitiligo patients will receive oral baricitinib plus narrow band ultraviolet rays B phototherapy for 3 to 6 months and serum s100B will be measured before the start of the treatment and after three months of the treatment.
No_intervention: control
healthy matched controls for them serum s100B will be measured
Active_comparator: oral mini pulse
vitiligo patients will recieve oral mini pulse therapy plus phototherapy for three to six months ,serum s100B will be measured before and three months after start of the treatment.
Related Therapeutic Areas
Sponsors
Leads: South Valley University